Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Viatris Inc. clinical trials
The registry lists 777 studies whose lead sponsor is Viatris Inc. or one of 21 companies grouped under it. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.
Keep track of what changes. Save the Viatris Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Viatris Inc..
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.434 studies →Acquired — became part of Viatris Inc., Nov 16, 2020 · source ↗
Something wrong?
- Mylan Pharmaceuticals Inc160 studies →Acquired — became part of Viatris Inc., Nov 16, 2020 · source ↗
Something wrong?
- 44 studies →
- MEDA Pharma GmbH & Co. KG24 studies →Acquired — became part of Viatris Inc., Nov 16, 2020 · source ↗
Something wrong?
- Viatris Innovation GmbH24 studies →Subsidiary
Something wrong?
- 21 studies →
- 19 studies →
- Mylan Bertek Pharmaceuticals13 studies →Acquired — became part of Viatris Inc., Nov 16, 2020 · source ↗
Something wrong?
- Oyster Point Pharma, Inc.11 studies →Acquired — became part of Viatris Inc., Jan 3, 2023 · source ↗
Something wrong?
- Viatris Inc.6 studiesSame company
Something wrong?
- 5 studies →
- Viatris Specialty LLC5 studies →Subsidiary
Something wrong?
- 2 studies →
- Viatris Pharmaceuticals Co., Ltd.1 study →Regional office
Something wrong?
- Viatris Pharmaceuticals Japan Inc1 study →Regional office
Something wrong?
- Mylan Pharmaceuticals Private Limited1 study →Acquired — became part of Viatris Inc., Nov 16, 2020 · source ↗
Something wrong?
- 1 study →
- 1 study →
- Viatris Korea1 study →Regional office
Something wrong?
- Famy Life Sciences, a Viatris Company1 study →Subsidiary
Something wrong?
- Mylan Technologies Inc.1 study →Acquired — became part of Viatris Inc., Nov 16, 2020 · source ↗
Something wrong?
- BGP Products Operations GmbH, a Viatris company1 study →Subsidiary
Something wrong?
Focus areas
Conditions Viatris Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 777. Browse all 777 →
- Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid UsersRecruitingNCT07813026Phase 4
- Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus ErythematosusEnrolling by invitationNCT06475742Phase 3
Sponsor listed in the registry: Viatris Innovation GmbH
- A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentRecruitingNCT07201129Phase 3
Sponsor listed in the registry: Viatris Innovation GmbH
- Selatogrel Outcome Study in Suspected Acute Myocardial InfarctionEnrolling by invitationNCT04957719Phase 3
Sponsor listed in the registry: Viatris Innovation GmbH
- A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary SyndromeRecruitingNCT07615868Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- Investigating Ovulation Inhibition for Use as a ContraceptiveRecruitingNCT07365904Phase 2
Sponsor listed in the registry: Mylan Pharmaceuticals Inc · First submitted after Mylan Pharmaceuticals Inc became part of Viatris Inc.
- Safety and Efficacy Evaluation of <Dovprela Tablets 200 mg> by Post-marketing SurveillanceRecruitingNCT06471088
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting ConditionsNot yet recruitingNCT06273254Phase 1
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting ConditionsNot yet recruitingNCT06266988Phase 1
- Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing PotentialActive, not recruitingNCT06672016Phase 3
Sponsor listed in the registry: Mylan Pharmaceuticals Inc · First submitted after Mylan Pharmaceuticals Inc became part of Viatris Inc.
- Dymista in Chinese AdolescentsActive, not recruitingNCT07597473Phase 4
- A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus ErythematosusActive, not recruitingNCT05672576Phase 3
Sponsor listed in the registry: Viatris Innovation GmbH
- A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus ErythematosusActive, not recruitingNCT05648500Phase 3
Sponsor listed in the registry: Viatris Innovation GmbH
- Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 CyclesCompletedNCT05139121Phase 3
Sponsor listed in the registry: Mylan Technologies Inc. · First submitted after Mylan Technologies Inc. became part of Viatris Inc.
- Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use ExperienceCompletedNCT07777965Phase 4
- Extension Study of MYL-1701P-3001 for Safety and EfficacyCompletedNCT04674800Phase 3
Sponsor listed in the registry: Mylan Pharmaceuticals Inc · First submitted after Mylan Pharmaceuticals Inc became part of Viatris Inc.
- A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery DiseaseCompletedNCT03384966Phase 2
Sponsor listed in the registry: Viatris Innovation GmbH
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus ErythematosusCompletedNCT02472795Phase 1/2
Sponsor listed in the registry: Viatris Innovation GmbH
- A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart AttackCompletedNCT03487445Phase 2
Sponsor listed in the registry: Viatris Innovation GmbH
- Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusCompletedNCT03742037Phase 2
Sponsor listed in the registry: Viatris Innovation GmbH
- A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)Active, not recruitingNCT07266090Phase 2
Sponsor listed in the registry: Viatris Pharmaceuticals Co., Ltd.
- A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy ParticipantsCompletedNCT07133191Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male ParticipantsCompletedNCT07301723Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.Active, not recruitingNCT06052995
Sponsor listed in the registry: BGP Products Operations GmbH, a Viatris company
- Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following HerniorrhaphyCompletedNCT06215859Phase 3
Sponsor listed in the registry: Viatris Specialty LLC
- Real-world Evidence Study on CystistatCompletedNCT05544695
Sponsor listed in the registry: MEDA Pharma GmbH & Co. KG · First submitted after MEDA Pharma GmbH & Co. KG became part of Viatris Inc.
- A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic OintmentTerminatedNCT06400511Phase 3
Sponsor listed in the registry: Famy Life Sciences, a Viatris Company
- Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following BunionectomyCompletedNCT06215820Phase 3
Sponsor listed in the registry: Viatris Specialty LLC
- Study to Evaluate the Effectiveness of Legalon®CompletedNCT05051527
Sponsor listed in the registry: Mylan Inc. · First submitted after Mylan Inc. became part of Viatris Inc.
- Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian SubjectsCompletedNCT04052360Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441TerminatedNCT02479204Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of CenerimodCompletedNCT04819464Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- A Study to Evaluate Cenerimod in Healthy Male SubjectsCompletedNCT02914223Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.CompletedNCT04255277Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- The Effect of Severe Kidney Impairment on Cenerimod PharmacokineticsCompletedNCT05004311Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- The Effect of Reduced Liver Function on Selatogrel PharmacokineticsCompletedNCT04406896Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy SubjectsCompletedNCT04557280Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy SubjectsCompletedNCT03814200Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- A Study to Evaluate ACT-246475 Fate in Healthy Male SubjectsCompletedNCT03593278Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy SubjectsCompletedNCT03430661Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the BodyCompletedNCT03173625Phase 1
Sponsor listed in the registry: Viatris Innovation GmbH
- Phase 4 Study Evaluating the Safety of the Nasal Guide With TyrvayaCompletedNCT05918406Phase 4
Sponsor listed in the registry: Oyster Point Pharma, Inc. · First submitted after Oyster Point Pharma, Inc. became part of Viatris Inc.
- A Study Evaluating the Safety of the Nasal PumpTerminatedNCT06329687Phase 4
Sponsor listed in the registry: Oyster Point Pharma, Inc. · First submitted after Oyster Point Pharma, Inc. became part of Viatris Inc.
- Dose-finding Study of MR-130A-01 Contraceptive Transdermal PatchCompletedNCT06048536Phase 2
Sponsor listed in the registry: Mylan Pharmaceuticals Inc · First submitted after Mylan Pharmaceuticals Inc became part of Viatris Inc.
- Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)CompletedNCT05046795Phase 3
Sponsor listed in the registry: Mylan Pharma UK Ltd. · First submitted after Mylan Pharma UK Ltd. became part of Viatris Inc.
- Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse ExperienceCompletedNCT04570436Phase 4
Sponsor listed in the registry: Viatris Specialty LLC
- Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic KeratopathyCompletedNCT04957758Phase 2
Sponsor listed in the registry: Oyster Point Pharma, Inc. · First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc.
- Fasting Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mgCompletedNCT00650273Phase 1
Sponsor listed in the registry: Mylan Pharmaceuticals Inc · First submitted before Mylan Pharmaceuticals Inc became part of Viatris Inc.
- Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mgCompletedNCT00648765Phase 1
Sponsor listed in the registry: Mylan Pharmaceuticals Inc · First submitted before Mylan Pharmaceuticals Inc became part of Viatris Inc.
- Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate TabletsCompletedNCT00650520Phase 1
Sponsor listed in the registry: Mylan Pharmaceuticals Inc · First submitted before Mylan Pharmaceuticals Inc became part of Viatris Inc.